Michael A. Morse, MD, MHS

Related Content

Services

• Esophageal Cancer
• Gastrointestinal Cancer

Department / Division:
Medicine / Medical Oncology

Address:
DUMC 3233
Durham, NC 27710

Appointment Telephone:
919-668-6688

Office Telephone:
919-681-3480

Fax Telephone:
919-681-0874

• MD, Yale University School of Medicine, Connecticut, 1990

• Internal Medicine, University of Washington, 1990-1993

• Hematology/Oncology, Duke University Medical Center, 1993-1996

• MHS, Duke University Medical Center, 2000

Clinical Interests:
Gastrointestinal malignancies, hepatic tumors, immunotherapy, melanoma

Research Interests:
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma.  These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for:  patients with metastatic malignancies expressing CEA, high risk resected malignancies such as breast, colon, and lung cancer. We are performing a clinical trial of adoptive transfer of CMV specific T cells in conjunction with the BMT program.

My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

For more information, see http://arcadia.mc.duke.edu/LyerlyLab/body_index.html

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Representative Publications:
Mosca PJ, Lyerly HK, Ching CD, Hobeika AC, Clay TM, Morse MA. Proteomics for monitoring immune responses to cancer vaccines. Curr Opin Mol Ther. 2003 Feb;5(1):39-43. (2003) Abstract

Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, Lyerly HK. HER2 Dendritic Cell Vaccines. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S164-72. (2003) Abstract

Bunce CJ, Morse MA. A need for effective adjuvants. Curr Opin Mol Ther. 2003 Feb;5(1):8-9. (2003) Abstract

Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002 Sep;72(3):546-53. (2002) Abstract

Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, Vredenburgh JJ, Chao NJ, Clay TM, Mosca PJ, Lyerly HK. Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. J Hematother Stem Cell Res. 2002 Aug;11(4):659-68. (2002) Abstract

Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer. 2002;32(1):1-6. (2002) Abstract

Morse MA, Mosca PJ, Clay TM, Lyerly HK. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther. 2002 Jan;2(1):35-43. (2002) Abstract

Morse MA, Lyerly HK. DNA and RNA modified dendritic cell vaccines. World J Surg. 2002 Jul;26(7):819-25. (2002) Abstract

Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther. 2002 Dec;2(8):827-34. (2002) Abstract

Morse MA, Clay TM, Lyerly HK. Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther. 2002 Mar;2(3):237-47. (2002) Abstract

Morse MA, Clay TM, Lyerly HK. CEA loaded dendritic cell vaccines. Cancer Chemother Biol Response Modif. 2002;20:385-90. (2002) Abstract

Clavien PA, Kang KJ, Selzner N, Morse MA, Suhocki PV. Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. J Gastrointest Surg. 2002 Jan-Feb;6(1):95-101. (2002) Abstract

Bunce CJ, Morse MA. Priming, boosting, measuring. Curr Opin Mol Ther. 2002 Feb;4(1):13-4. (2002) Abstract

White RR, Paulson EK, Freed KS, Keogan MT, Hurwitz HI, Lee C, Morse MA, Gottfried MR, Baillie J, Branch MS, Jowell PS, McGrath KM, Clary BM, Pappas TN, Tyler DS. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg. 2001 Nov-Dec;5(6):626-33. (2001) Abstract

White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, Gottfried MR, Baillie J, Branch MS, Jowell PS, McGrath KM, Clary BM, Pappas TN, Tyler DS. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001 Dec;8(10):758-65. (2001) Abstract

Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, Cullen BR. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol. 2001 Aug;75(15):6776-85. (2001) Abstract

Selzner M, Bielawska A, Morse MA, Rüdiger HA, Sindram D, Hannun YA, Clavien PA. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001 Feb 1;61(3):1233-40. (2001) Abstract

Mosca PJ, Hobeika AC, Clay TM, Morse MA, Lyerly HK. Direct detection of cellular immune responses to cancer vaccines. Surgery. 2001 Mar;129(3):248-54. (2001) Abstract

Morse MA. Technology evaluation: VEGF165 gene therapy, Valentis Inc. Curr Opin Mol Ther. 2001 Feb;3(1):97-101. (2001) Abstract

Morse MA. Technology evaluation: ISIS-2503, Isis Pharmaceuticals. Curr Opin Mol Ther. 2001 Dec;3(6):589-94. (2001) Abstract

Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr Opin Mol Ther. 2001 Aug;3(4):407-12. (2001) Abstract

Morse MA. Technology evaluation: BLP-25, Biomira Inc. Curr Opin Mol Ther. 2001 Feb;3(1):102-5. (2001) Abstract

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Surrogate markers of response to cancer immunotherapy. Expert Opin Biol Ther. 2001 Mar;1(2):153-8. (2001) Abstract

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Monitoring cellular immune responses to cancer immunotherapy. Curr Opin Mol Ther. 2001 Feb;3(1):45-52. (2001) Abstract

Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA. 2001 Mar 7;285(9):1201-5. (2001) Abstract

Lyerly HK, Morse MA, Clay TM. Surrogate markers of effective anti-tumor immunity. Ann Surg Oncol. 2001 Apr;8(3):190-1. (2001) Abstract

Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol. 2001;21(1-3):287-97. (2001) Abstract

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res. 2001 May;7(5):1127-35. (2001) Abstract